| ||
| FDA Approves Test That Spots HER2-Positive Breast Cancers U.S. News & World Report TUESDAY, June 14 (HealthDay News) -- A new genetic test that helps determine if breast cancer patients are good candidates for treatment with the drug Herceptin was approved Tuesday by the US Food and Drug Administration. About 20 percent of breast ... See all stories on this topic » | ||
| Simple carb sugar feeds cancerous tumours: Study The Province "And, this diet not only prevented weight gain, it reduced cancer development and death in mice genetically predisposed to breast cancer." Krystal's team compared the average (poor) Western diet to a low-carb, high-protein diet. ... See all stories on this topic » | ||
| Christina Patterson: We can't keep paying people to be poor The Independent "So," she said, because she's very polite, and thinks you should make small talk, even when you've just been diagnosed with breast cancer, and lost your breast, and are in what doctors like to call discomfort, "what, when you're not in hospital having ... See all stories on this topic » | ||
| New Test Helps Evaluate Breast Cancer Patients for Herceptin Use Health.com TUESDAY, June 14 (HealthDay News) — A genetic test to help doctors evaluate whether women with breast cancer are candidates for treatment with the drug Herceptin (trastuzumab) has been approved by the US Food and Drug Administration. ... See all stories on this topic » | ||
| FDA Approves Test to Determine HER2 Status in Breast Cancer Medscape June 14, 2011 — The US Food and Drug Administration (FDA) has approved the Inform Dual ISH, a genetic test that can help determine if breast cancer patients are HER2-positive and, therefore, candidates for treatment with trastuzumab (Herceptin). ... See all stories on this topic » | ||
| FDA approves new test to help determine if breast cancer patients are ... Pharmaceutical Processing The US Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer ... See all stories on this topic » | ||
| Ventana Medical Systems, Inc. Receives FDA Approval for the First Fully ... istockAnalyst.com (press release) This is the first fully automated assay approved by the FDA for determination of HER2 gene status in breast cancer as an aid in the assessment of patients considered for treatment with Herceptin (trastuzumab). For breast cancer patients, waiting days ... See all stories on this topic » | ||
|
| ||
| resources - http://resources.zeblog.com/ By resources As with the anti-cancer drug paclitaxel injection can greatly extend Herceptin combined with advanced breast cancer and ovarian cancer survival, the international market is expected to semi-synthetic paclitaxel API will continue to ... resources | ||
| Synthetic Biology companies Ziopharm and Intrexon By noreply@blogger.com (bw) Ziopharm Oncology Inc's Chief Executive Jonathan Lewis plans to produce less expensive new cancer drugs using synthetic biology. Lewis says Ziopharm's most advanced drug in development, palifosfamide for sarcoma and lung cancer, ... is expected to have several potential benefits including oral dosing, application in multi-drug resistant tumors, no neuropathy and a quite tolerable toxicity profile. It is currently being studied in Phase I/II in metastatic breast cancer. ... Next Big Future |
| ||
| Study: Pfizer drug lowers risk of breast cancer | Product Design ... Pfizer drug offers new option for preventing breast cancer; fewer side effects than tamoxifen. www.pddnet.com/news-ap-study-pfizer-drug-lowers-risk-of-b... | ||
| News - Penn State Hershey Medical Center The Food and Drug Administration approved lapatinib in 2007 for use as a breast cancer chemotherapy. It blocks two specific types of proteins located on ... pennstatehershey.org/web/guest/home/news/-/.../2862586 |
Tip: Use a minus sign (-) in front of terms in your query that you want to exclude. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment